Cardiac amyloidosis (CA) is a progressive and life-threatening cardiomyopathy characterized by deposition of misfolded proteins in the myocardium, leading to heart failure (HF), conduction disorders, and (supra)ventricular arrhythmias. Disease prognosis is mainly determined by (a) the presence of HF at time of diagnosis and (b) etiology of the misfolded proteins (i.e. light chain (AL) or transthyretin [TTR] amyloidosis [ATTR]), with a median survival of ˜3.5 years, if left untreated [1]. Due to a lack of treatment options in the past, CA was considered untreatable resulting often in underdiagnosis of the disease [2].
